Author:
Calopedos R J S,Chalasani V,Asher R,Emmett L,Woo H H
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Urology,Oncology
Reference37 articles.
1. Conford P, Bellmunt J, Bolla M, Briers E, De Santis M, Gross T et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic and castration-resistant prostate cancer. Eur Urol 2017; 71: 630–642.
2. Kulkarni HR, Singh A, Schuchardt C, Niepsch K, Sayeg M, Leshch Y et al. PSMA-based radioligand therapy for metastatic castration-resistant prostate cancer: the bad berka experience 2013. J Nucl Med 2016; 57: 97S–104S.
3. Baum RP, Kulkarni HR, Schuchardt C, Singh A, Wirtz M, Wiessalla S et al. 177Lu-labeled prostate-specific membrane antigen radioligand therapy of metastatic castration-resistant prostate cancer: safety and efficacy. J Nucl Med 2016; 57: 1006–1013.
4. Liu H, Rajasekaran AK, Moy P, Xia Y, Kim S, Navarro V et al. Constitutive and antibody-induced internalization of prostate-specific membrane antigen. Cancer Res 1998; 58: 4055–4060.
5. Liu H, Moy P, Kim S, Xia Y, Rajasekaran A, Navarro V et al. Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumour vascular endothelium. Cancer Res 1997; 57: 3629–3634.
Cited by
73 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献